The whisper you refered to apparently did not worry the shorts here, at this juncture, relative to today's open.
Biotech is fraught with potholes in the path to FDA approval. Just look at ZIOP and INFI as two recent examples. I'm long ARRY but aware of the rocky path to approval. Whispers don't count; clinically relevant data does. And that data should point to a drug that's best in class, with a large or at least strong niche market. GLTA